Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results

Core Insights - Pelthos Therapeutics Inc. reported a significant growth in net product revenue for ZELSUVMI, achieving $9.1 million in the fourth quarter of 2025, which is a 28% increase from the previous quarter [1][8]. - The total net product revenue for ZELSUVMI from its launch in July 2025 through December 31, 2025, reached $16.2 million, contributing to a total revenue of $16.8 million for the year [1][4]. Revenue and Sales Performance - A total of 8,948 ZELSUVMI units were prescribed by 2,712 unique prescribers in fiscal year 2025, with a remarkable 129% quarter-over-quarter increase in units dispensed from 2,716 in Q3 2025 to 6,232 in Q4 2025 [2][4]. - The company anticipates continued strong growth for ZELSUVMI in 2026, supported by the capital raised through financing activities [5]. Financial Overview - The cost of goods sold for the fourth quarter of 2025 was $1.7 million, down from $2.3 million in the third quarter, indicating improved cost management [8]. - Selling, general, and administrative (SG&A) expenses decreased from $19.6 million in Q3 2025 to $18.5 million in Q4 2025, reflecting a 6% reduction [8]. - The operating loss improved from approximately $15.4 million in Q3 2025 to $12.0 million in Q4 2025, showing progress towards achieving positive cash flow [8]. Strategic Developments - In November 2025, the company completed the acquisition of XEPI®, a topical treatment for impetigo, enhancing its dermatology product portfolio [4][5]. - The acquisition of XEGLYZE® in January 2026 further diversifies the product offerings, targeting head lice infestations, which is prevalent among children [4][5]. - The company secured an $18.0 million private convertible notes financing in November 2025 and a $50.0 million senior secured term loan facility in January 2026, providing necessary capital for growth initiatives [4][5]. Market Positioning - Pelthos Therapeutics is focused on addressing unmet patient needs in the dermatology space, particularly for conditions affecting children, which aligns with the target market for its products [10]. - The company believes it is well-positioned to capitalize on large addressable markets with its portfolio of ZELSUVMI, XEPI, and XEGLYZE, leveraging existing commercial relationships to drive revenue growth [5].